Reduced apolipoprotein ϵ4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals

Recent genetic studies show that the apolipoprotein E ϵ4 allele (ApoE- ϵ4) is a risk factor for Alzheimer's disease (AD). If ApoE- ϵ4 individuals develop AD as they get older, we would expect a decrease in ApoE- ϵ4 allele frequency with increasing age. We found a marked decline in ApoE- ϵ4 allele frequency with advancing age in both AD and cognitively normal controls (p < 0.003), although in all age groups the ApoE- ϵ4 allele was overrepresented (p < 0.0001). Nonetheless, a few cognitively normal nonagenarians were ApoE- ϵ4 positive. Thus, our data support two new conclusions: (1) the ApoE- ϵ4 associated risk for AD is age-dependent, probably due to censoring by the earlier development of AD in ApoE- ϵ4 individuals, and (2) despite the ApoE- ϵ4 associated risk for AD, it is possible to reach extreme old age with normal cognition.

[1]  P. Froguel,et al.  Genetic associations with human longevity at the APOE and ACE loci , 1994, Nature Genetics.

[2]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[3]  P. Wilson,et al.  Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. , 1987, Journal of lipid research.

[4]  S. Fahn Fluctuations of disability in Parkinson's disease: pathophysiology , 1981 .

[5]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[6]  W R Woodward,et al.  Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[7]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Schellenberg,et al.  Apolipoprotein E genotype and Alzheimer's disease , 1993, The Lancet.

[9]  J. Nutt On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics , 1987, Annals of neurology.

[10]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.